Maplight Therapeutics, Common Stock Alpha and Beta Analysis
| MPLT Stock | 18.01 0.11 0.61% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MapLight Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in MapLight Therapeutics, over a specified time horizon. Remember, high MapLight Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MapLight Therapeutics,'s market risk premium analysis include:
Beta 0.83 | Alpha 0.0848 | Risk 6.61 | Sharpe Ratio 0.0233 | Expected Return 0.15 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out MapLight Therapeutics, Backtesting, MapLight Therapeutics, Valuation, MapLight Therapeutics, Correlation, MapLight Therapeutics, Hype Analysis, MapLight Therapeutics, Volatility, MapLight Therapeutics, History and analyze MapLight Therapeutics, Performance. MapLight Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MapLight Therapeutics, market risk premium is the additional return an investor will receive from holding MapLight Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MapLight Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MapLight Therapeutics,'s performance over market.| α | 0.08 | β | 0.83 |
MapLight Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of MapLight Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how MapLight Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.MapLight Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how MapLight Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading MapLight Therapeutics, shares will generate the highest return on investment. By understating and applying MapLight Therapeutics, stock market price indicators, traders can identify MapLight Therapeutics, position entry and exit signals to maximize returns.
MapLight Therapeutics, Return and Market Media
The median price of MapLight Therapeutics, for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 16.75 with a coefficient of variation of 15.32. The daily time series for the period is distributed with a sample standard deviation of 2.56, arithmetic mean of 16.69, and mean deviation of 2.2. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Roundup Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements - PharmExec.com | 10/28/2025 |
2 | MapLight Therapeutics Closes Successful IPO and Private Placement - MSN | 10/30/2025 |
3 | Maplight Therapeutics Hits New 1-Year Low Heres What Happened | 11/26/2025 |
4 | MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress | 12/04/2025 |
5 | Maplight Therapeutics Raised to Hold at Wall Street Zen | 12/22/2025 |
About MapLight Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MapLight or other stocks. Alpha measures the amount that position in MapLight Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 | 2025 (projected) | PB Ratio | 36.41 | 10.66 | 6.6 | 6.27 | Capex To Depreciation | 1.3 | 0.83 | 1.1 | 1.19 |
MapLight Therapeutics, Investors Sentiment
The influence of MapLight Therapeutics,'s investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in MapLight. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to MapLight Therapeutics,'s public news can be used to forecast risks associated with an investment in MapLight. The trend in average sentiment can be used to explain how an investor holding MapLight can time the market purely based on public headlines and social activities around MapLight Therapeutics, Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
MapLight Therapeutics,'s market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for MapLight Therapeutics,'s and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average MapLight Therapeutics,'s news discussions. The higher the estimated score, the more favorable is the investor's outlook on MapLight Therapeutics,.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards MapLight Therapeutics, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, MapLight Therapeutics,'s short interest history, or implied volatility extrapolated from MapLight Therapeutics, options trading.
Build Portfolio with MapLight Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics,'s price analysis, check to measure MapLight Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics, is operating at the current time. Most of MapLight Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics,'s price. Additionally, you may evaluate how the addition of MapLight Therapeutics, to your portfolios can decrease your overall portfolio volatility.